Ardena expands bioanalytical services in Europe
Ghent, Belgium, 29th October 2024 – Ardena, a global CDMO that offers integrated services for drug development, is strengthening its bioanalytical services with a new laboratory and investments in Europe.
Following the recent expansion in the US, Ardena is further strengthening their capabilities with the establishment of a new bioanalytical lab at our Pivot Park facility in Oss. This along with new GLP capabilities and increased capacity at the Bioanalytical Centre of Excellence in Assen.
The new lab in Pivot Park should be operational in the first quarter of 2025 and will offer advanced analytical testing services for both small and large molecules. It will use advanced technologies such as LC-MS/MS and fluorometric detection assays, along with the ELISA-based Gyrolab automated technology platform. Ardena’s investments in Assen will strengthen capabilities in immunochemistry, flow cytometry and qPCR, while increasing LC-MS/MS capabilities and introducing new automated Hamilton systems for improved efficiency.
This strategic expansion is designed to meet the increasing demand for comprehensive and state-of-the-art bioanalytical services, allowing Ardena to offer greater flexibility in project times and faster turnaround times.
For more information, read the press release here.
Find more news here.